Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation
Thomas Z. Benton, Catherine M. Mills, Jonathan M. Turner, Megan J. Francis, Dalan J. Solomon, Pieter B. Burger, Yuri K. Peterson, Nathan G. Dolloff, André S. Bachmann, Patrick M. Woster
Abstract
. We are currently optimizing these inhibitors for use in immunotherapy. These small molecule inhibitors of the CD38-hydrolase or cyclase activity can serve as chemical probes to determine the mechanism by which CD38 promotes resistance to MAB therapy, and could become novel and effective therapeutic agents that produce immunostimulatory effects. Our studies have identified the first small molecule inhibitors of CD38 specifically for use as immunostimulants.
Topics & Concepts
CD38Immune systemMonoclonal antibodyChemistrySmall moleculeCyclaseCancer researchPharmacologyBiochemistryBiologyCell biologyImmunologyEnzymeAntibodyStem cellCD34Calcium signaling and nucleotide metabolismAdenosine and Purinergic SignalingToxin Mechanisms and Immunotoxins